RARE
Ultragenyx
14.90$
-4.7%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 94.7% | 80.5% | 92.1% | 49.8% | 72.6% | 74.9% | 73.6% | 56.3% | 57.2% | 49.1% | 54.3% | 62.1% | |
| 12.3% | 16.7% | 29.8% | 20.5% | 15.8% | 38.2% | 40.6% | 20.2% | 8.6% | 14.3% | 11.6% | 28.3% | |
| 94.7% | 78.1% | 92.1% | 49.8% | 63.9% | 66.5% | 68.3% | 48.6% | 48.4% | 38.7% | 40.6% | 45.2% | |
| – | – | – | 1.1% | 1.8% | 2.9% | 1.3% | 2.9% | 2.6% | 4.9% | 8.1% | 10.4% | |
| 0.0% | 0.0% | 0.0% | 0.2% | 1.0% | 1.0% | 0.7% | 1.1% | 1.7% | 2.3% | 3.0% | 3.4% | |
| 1.5% | 1.3% | 3.2% | 4.4% | 2.8% | 6.6% | 4.2% | 9.3% | 16.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 9.0% | 6.2% | 3.9% | 2.5% | 2.9% | 2.9% | 3.0% | 3.0% | 2.9% | |
| 0.0% | 0.0% | 0.0% | 28.8% | 18.0% | 11.4% | 7.5% | 8.6% | 10.4% | 11.2% | 11.9% | 11.5% | |
| 6.6% | 5.1% | 12.3% | 21.9% | 15.4% | 42.4% | 34.4% | 39.4% | 77.2% | 81.5% | 82.6% | 104.8% | |
| 6.3% | 5.0% | 11.1% | 14.5% | 10.4% | 9.1% | 10.8% | 11.9% | 16.9% | 18.8% | 22.9% | 25.1% | |
| – | – | – | – | – | 0.6% | 0.5% | 0.7% | 0.8% | 0.8% | 0.7% | 5.3% | |
| 2.5% | 0.5% | 1.0% | 1.8% | 1.7% | 1.1% | 0.7% | 1.1% | 2.8% | 2.8% | 2.6% | 2.0% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 93.4% | 94.9% | 87.7% | 78.1% | 84.6% | 57.6% | 65.6% | 60.6% | 22.8% | 18.5% | 17.0% | -5.2% | |
| -70.2% | -50.9% | -98.1% | -169.7% | -143.2% | -126.2% | -92.0% | -136.2% | -179.9% | -227.2% | -263.2% | -295.8% | |
| 14.5% | 6.6% | 7.3% | 8.7% | 6.9% | 5.0% | 3.5% | 4.5% | 4.5% | 4.9% | 6.0% | 6.4% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.